2007: ACR Business Meeting and Late-Breaking Abstracts

ACR Business Meeting and Late-Breaking Abstracts

Saturday, November 10, 2007

L13

Mycophenolate Mofetil and Intravenous Cyclophosphamide in the Aspreva Lupus Management Study (ALMS): Efficacy by Racial Group

L14

Golimumab, A New, Human, TNF-alpha Antibody Administered As A Monthly Subcutaneous Injection In Psoriatic Arthritis: 24-week Efficacy And Safety Results Of The Randomized, Placebo-Controlled GO-REVEAL Study

L15

IL-6 Receptor Inhibition with Tocilizumab Reduces Disease Activity in Patients with Rheumatoid Arthritis with Inadequate Response to a Range of DMARDs: The TOWARD Study

L16

Phase II, Randomized, Placebo-Controlled Study of CNTO 1275, a Human Interleukin-12/23 Monoclonal Antibody, in Psoriatic Arthritis

L17

Remission Rates in Subjects With Active Early Rheumatoid Arthritis - 1 Year Results of the COMET Trial: Combination of Methotrexate and Etanercept in Active Early Rhuematoid Arthritis

L18

Pediatric Randomized Placebo-Controlled Trial of Alendronate for Glucocorticoid-Associated Osteoporosis

See more of: Late-Breaking Abstracts ACR Concurrent Abstract Session

<< Previous Session Level | Next Session Level >>